Proline catabolism is a key factor facilitating Candida albicans pathogenicity

PLoS Pathog. 2023 Nov 2;19(11):e1011677. doi: 10.1371/journal.ppat.1011677. eCollection 2023 Nov.

Abstract

Candida albicans, the primary etiology of human mycoses, is well-adapted to catabolize proline to obtain energy to initiate morphological switching (yeast to hyphal) and for growth. We report that put1-/- and put2-/- strains, carrying defective Proline UTilization genes, display remarkable proline sensitivity with put2-/- mutants being hypersensitive due to the accumulation of the toxic intermediate pyrroline-5-carboxylate (P5C), which inhibits mitochondrial respiration. The put1-/- and put2-/- mutations attenuate virulence in Drosophila and murine candidemia models and decrease survival in human neutrophils and whole blood. Using intravital 2-photon microscopy and label-free non-linear imaging, we visualized the initial stages of C. albicans cells infecting a kidney in real-time, directly deep in the tissue of a living mouse, and observed morphological switching of wildtype but not of put2-/- cells. Multiple members of the Candida species complex, including C. auris, are capable of using proline as a sole energy source. Our results indicate that a tailored proline metabolic network tuned to the mammalian host environment is a key feature of opportunistic fungal pathogens.

MeSH terms

  • Animals
  • Candida
  • Candida albicans*
  • Humans
  • Mammals
  • Mice
  • Proline / metabolism
  • Saccharomyces cerevisiae* / genetics
  • Virulence

Substances

  • Proline

Grants and funding

The research in the collaborating laboratories was supported by the following granting agencies: The Swedish Research Council 2019-01547, 2022-01190 (POL), 2019-01790 (CP), and 2022-00850 (CFU); the Marie Curie - Initial Training Network (ITN) ImResFun 606786 (POL, KK, SR, TL); the China MOST Key R&D Program 2022YFC2303200 and 2020YFA 0907200 (CC); the National Natural Science Foundation of China 32311530119 and 32170195 (CC); the Shanghai “Belt and Road” Joint Laboratory Project 22490750200 (CC); the Austrian Science Fund (FWF) ChromFunVir P-32582 (KK); and the European Commission, FP7 Framework Programme, Fungitect 602125 (TL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.